Putnam Investments’s Corcept Therapeutics CORT Stock Holding History

Putnam Investments’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$797K	Sell	24,543 -775	-3%	-$21.3K	﹤0.01%	869
2023 Q3	$690K	Buy	25,318 +7,151	+39%	+$207K	﹤0.01%	880
2023 Q2	$404K	Sell	18,167 -567	-3%	-$13.1K	﹤0.01%	980
2023 Q1	$406K	Sell	18,734 -153,914	-89%	-$3.37M	﹤0.01%	986
2022 Q4	$3.51M	Buy	172,648 +6,254	+4%	+$157K	0.01%	562
2022 Q3	$4.27M	Sell	166,394 -52,165	-24%	-$1.4M	0.01%	470
2022 Q2	$5.2M	Buy	+218,559	New	+$4.76M	0.01%	428

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Putnam Investments's CORT Position: Q4 2023 in Review

Putnam Investments reduced its Corcept Therapeutics (CORT) stake by 3.1% in Q4 2023, selling an estimated $21.3K and leaving 24,543 shares worth $797K. The position accounts for ﹤0.01% of the portfolio, ranked #869.

Putnam Investments first reported a position in CORT in Q2 2022 and has held it in 7 quarters since. The position peaked at $5.2M in Q2 2022. 273 funds tracked by Wall St. Rank hold CORT as of Q4 2023.

Putnam Investments held 24,543 shares of Corcept Therapeutics worth $797K as of Q4 2023.
Putnam Investments sold 775 Corcept Therapeutics shares in Q4 2023, an estimated $21.3K.
Corcept Therapeutics made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #869 holding.
Putnam Investments first reported a position in Corcept Therapeutics in Q2 2022 and has held it in 7 quarters since.
Putnam Investments's Corcept Therapeutics position peaked at $5.2M in Q2 2022.
273 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.